NCT03413618View on ClinicalTrials.gov

Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis

PHASE4CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

December 20, 2017

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Deep Vein ThrombosisPostthrombotic Syndrome
Interventions
DRUG

Rivaroxaban

15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month

DRUG

Diosmin

600 mg q.d. for 12 month

OTHER

compression stockings

above knee stocking for 12 month

Trial Locations (1)

121352

Clinical Hospital no.1 of the President's Administration of Russian Federation, Moscow

All Listed Sponsors
lead

Pirogov Russian National Research Medical University

OTHER

NCT03413618 - Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis | Biotech Hunter | Biotech Hunter